Inbec是哪里产的？

Suimeike (dolute abalamide tablets, Inbec) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B*5701 allele, he should not take products containing abacavir. For adults and adolescents (body weight not less than 40 kg), the recommended dosage of Trimax (Inbec) is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax (Inbec) is a fixed-dose tablet and cannot be reduced. Where is Suimeikai (Dotiabalamid Tablets, Inbec) produced?

The more cost-effective Indian version of Suimeikan (Abalamid Tablets, Inbec) is developed and produced by the Indian company Emcure. A box of 30 tablets sells for about RMB 1,000. If patients choose this Indian Suimeike (Dolutea, Inbec), they can go to India to buy it in person, but it is best to obtain Suimeike (Dolutea, Inbec) through domestic professional overseas medical service institutions.

As a compound preparation, Suimeike (Dolutea Paramid Tablets, Inbec) can achieve the effect of combined medication by taking one drug. The antiviral effect of this drug is similar to that of tenofovir, but it has less damage to mitochondria, thereby reducing fat consumption, pancreatitis, neuritis, lactic acidosis and other adverse reactions. Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). Existing research shows that one year (48 weeks) after HIV-infected patients were treated with TRIUMEQ, the viral load of 93% of the infected patients became negative. Suimeikai (dolute abalamib tablets, Inbec) has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.